Literature DB >> 21784527

The experiences of patients with pulmonary arterial hypertension receiving continuous intravenous infusion of epoprostenol (Flolan) and their support persons.

Heather Hall1, Joanne Côté, Althea McBean, Margaret Purden.   

Abstract

OBJECTIVE: Little is known about the day-to-day experiences of patients and their support persons during the course of epoprostenol treatment for pulmonary arterial hypertension (PAH). The study objective was to describe the experiences of patients and their support persons adjusting to PAH and continuous intravenous epoprostenol.
METHODS: A qualitative descriptive design with semistructured interviews was conducted jointly with the patient and his/her support person. Seven patients and their support persons (spouse, child, friend) were included.
RESULTS: Patients demonstrated personal growth and resilience as they adapted to PAH. Four patient themes emerged: initial shock, figuring it out, giving life, and ongoing struggles. Themes specific to the support person included "their life is in my hands," pressure to perform, and continuation of my role.
CONCLUSION: Nurses may assist these patients and support persons by teaching technical skills, problem-solving and troubleshooting strategies, mobilizing social support, and providing opportunities to reflect on lifestyle changes and long-term adjustment to PAH.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21784527     DOI: 10.1016/j.hrtlng.2011.05.007

Source DB:  PubMed          Journal:  Heart Lung        ISSN: 0147-9563            Impact factor:   2.210


  7 in total

1.  An advanced protocol-driven transition from parenteral prostanoids to inhaled trepostinil in pulmonary arterial hypertension.

Authors:  Ronald Oudiz; Manyoo Agarwal; Franz Rischard; Teresa De Marco
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

2.  Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis.

Authors:  Ci Song; Peter Kunovszki; Amélie Beaudet
Journal:  J Health Econ Outcomes Res       Date:  2022-06-08

3.  Ambulatory Transition from Parenteral Prostanoid to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension.

Authors:  Lucas M Kimmig; Chuanhong Liao; Remzi Bag
Journal:  Lung       Date:  2020-01-07       Impact factor: 3.777

4.  Adults' experiences of living with pulmonary hypertension: a thematic synthesis of qualitative studies.

Authors:  Gregg Harry Rawlings; Nigel Beail; Iain Armstrong; Robin Condliffe; David G Kiely; Ian Sabroe; Andrew R Thompson
Journal:  BMJ Open       Date:  2020-12-07       Impact factor: 2.692

5.  Health-related quality of life and disease progression in pulmonary arterial hypertension patients: a 3-year study.

Authors:  Laurence Halimi; Carey M Suehs; Gregory Marin; Clement Boissin; Anne-Sophie Gamez; Isabelle Vachier; Nicolas Molinari; Arnaud Bourdin
Journal:  ERJ Open Res       Date:  2021-08-23

Review 6.  Examining the impact of pulmonary hypertension on nonprofessional caregivers: A mixed-methods systematic review.

Authors:  Gregg H Rawlings; Nigel Beail; Robin Condliffe; David G Kiely; Andrew R Thompson; Ian Sabroe; Iain Armstrong
Journal:  Pulm Circ       Date:  2022-04-22       Impact factor: 2.886

7.  Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension.

Authors:  Hubert Chen; Erika B Rosenzweig; S Karl Gotzkowsky; Carl Arneson; Andrew C Nelsen; Robert C Bourge
Journal:  Health Qual Life Outcomes       Date:  2013-03-06       Impact factor: 3.186

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.